Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world


Autoři: Yoon-Kyoung Sung aff001;  Sun-Young Jung aff002;  Hyoungyoung Kim aff001;  Seongmi Choi aff003;  Seul Gi Im aff003;  Yu Sang Lee aff003;  Eun Jin Jang aff004;  Soo-Kyung Cho aff001
Působiště autorů: Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea aff001;  College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea aff002;  Department of Statistics, Kyungpook National University, Buk-gu, Daegu, Republic of Korea aff003;  Department of Information Statistics, Andong National University, Andong, Republic of Korea aff004
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article
doi: 10.1371/journal.pone.0227960

Souhrn

Background

To identify factors for starting biosimilar TNF inhibitors (TNFI) in patients with rheumatic diseases.

Methods and finding

Using a national claims database, we identified patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS) who had used TNFIs since they were approved in Korea in 2004. We assessed changes in the proportion of each form of TNFI used between 2004 and 2017. We then selected patients starting on TNFIs between 2013 and 2017 to identify factors for starting biosimilars. In RA (n = 4,216), biosimilars were more likely to be initiated in clinics [odds ratio (OR) 2.54] and in the metropolitan area (OR, 2.02), but were less likely to be initiated in general hospitals (OR 0.40) or orthopedics (OR 0.44). In AS (n = 2,338), biosimilars were common at the hospital level (OR 2.20) and tended to increase over the years (OR 1.16), but were initiated less in orthopedics (OR 0.07). In addition, RA patients were more likely to initiate biosimilars in combination with methotrexate (OR 1.37), but biosimilars were not initiated frequently by patients with higher comorbidity scores (OR 0.97) or receiving glucocorticoids (OR 0.67). The patient factors favoring biosimilar in AS use were not clear.

Conclusions

In Korea, the proportion of biosimilar TNFIs has increased. Type of institution and physician specialty are more important than patient factors in affecting biosimilar use. In RA, biosimilar TNFIs tend to be initiated in combination with MTX, and are less likely to be initiated in patients taking glucocorticoids or in those with high comorbidities.

Klíčová slova:

Ankylosing spondylitis – Drug users – Gastroenterology and hepatology – Korea – NSAIDs – Physicians – Rheumatoid arthritis – Rheumatology


Zdroje

1. Schulze-Koops H, Skapenko A. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm. Rheumatology. 2017;56(suppl_4):iv30–iv48. doi: 10.1093/rheumatology/kex277 28903543

2. Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology—“O Brave New World”. Nature Reviews Rheumatology. 2012;8:430. doi: 10.1038/nrrheum.2012.84 22664834

3. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Annals of the rheumatic diseases. 2013;72(10):1605–12. doi: 10.1136/annrheumdis-2012-203091 23687259

4. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Annals of the rheumatic diseases. 2013;72(10):1613–20. doi: 10.1136/annrheumdis-2012-203090 23687260

5. Emery P, Vencovský J, Sylwestrzak A, Leszczyński P, Porawska W, Baranauskaite A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Annals of the rheumatic diseases. 2017;76(1):51–7. doi: 10.1136/annrheumdis-2015-207588 26150601

6. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the rheumatic diseases. 2017;76(6):960–77. doi: 10.1136/annrheumdis-2016-210715 28264816

7. Vashisht P, Sayles H, Cannella AC, Mikuls TR, Michaud K. Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials. Arthritis Care & Research. 2016;68(10):1478–88.

8. Nikiphorou E, Kautiainen H, Hannonen P, Asikainen J, Kokko A, Rannio T, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opinion on Biological Therapy. 2015;15(12):1677–83. doi: 10.1517/14712598.2015.1103733 26549204

9. Sung YK, Cho SK, Kim D, Won S, Choi CB, Bang SY, et al. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab. Rheumatology international. 2017;37(6):1007–14. Epub 2017/02/20. doi: 10.1007/s00296-017-3663-z 28214924

10. Schmitz EMH, Benoy-De Keuster S, Meier AJL, Scharnhorst V, Traksel RAM, Broeren MAC, et al. Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study. Clinical rheumatology. 2017;36(9):2129–34. Epub 2017/06/09. doi: 10.1007/s10067-017-3686-6 28593609

11. Codreanu C, Sirova K, Jarosova K, Batalov A. Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis. Current medical research and opinion. 2018;34(10):1763–9. Epub 2018/02/15. doi: 10.1080/03007995.2018.1441144 29439591

12. Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Annals of the rheumatic diseases. 2019;78(2):192–200. Epub 2018/11/07. doi: 10.1136/annrheumdis-2018-213474 30396903

13. Teeple A, Ginsburg S, Howard L, Huff L, Reynolds C, Walls D, et al. Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States. Current medical research and opinion. 2019:1–7. Epub 2019/01/09.

14. Frantzen L, Cohen JD, Trope S, Beck M, Munos A, Sittler MA, et al. Patients’ information and perspectives on biosimilars in rheumatology: a French nation-wide survey. Joint, bone, spine: revue du rhumatisme. 2019. Epub 2019/01/20.

15. Kravvariti E, Kitas GD, Mitsikostas DD, Sfikakis PP. Nocebos in rheumatology: emerging concepts and their implications for clinical practice. Nature reviews Rheumatology. 2018;14(12):727–40. Epub 2018/10/27. doi: 10.1038/s41584-018-0110-9 30361674

16. Germain V, Scherlinger M, Barnetche T, Schaeverbeke T. Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect. Annals of the rheumatic diseases. 2018. Epub 2018/10/26.

17. Kim JA, Yoon S, Kim LY, Kim DS. Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data. Journal of Korean medical science. 2017;32(5):718–28. Epub 2017/04/06. doi: 10.3346/jkms.2017.32.5.718 28378543

18. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Medical care. 1998;36(1):8–27. Epub 1998/02/07. doi: 10.1097/00005650-199801000-00004 9431328

19. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the rheumatic diseases. 2016;75(1):3–15. Epub 2015/05/15. doi: 10.1136/annrheumdis-2015-207524 25969430

20. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Annals of the rheumatic diseases. 2017;76(6):978–91. doi: 10.1136/annrheumdis-2016-210770 28087505

21. Scavone C, Sessa M, Clementi E, Corrao G, Leone R, Mugelli A, et al. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study. BioDrugs. 2018;32(6):607–17. doi: 10.1007/s40259-018-0313-2 30341487

22. Cohen H, Beydoun D, Chien D, Lessor T, McCabe D, Muenzberg M, et al. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. Advances in therapy. 2016;33(12):2160–72. Epub 2016/11/01. doi: 10.1007/s12325-016-0431-5 27798772

23. Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Tari DU, et al. How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009–2013. BioDrugs. 2015;29(4):275–84. Epub 2015/07/15. doi: 10.1007/s40259-015-0132-7 26169209

24. Scherlinger M, Schaeverbeke T. 'To switch or not to switch': the missing piece in the puzzle of biosimilar literature? Annals of the rheumatic diseases. 2019. Epub 2019/01/06.

25. Cho SK, Sung YK, Choi CB, Kwon JM, Lee EK, Bae SC. Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database. Rheumatology international. 2013;33(12):2985–92. Epub 2013/08/07. doi: 10.1007/s00296-013-2833-x 23918169


Článek vyšel v časopise

PLOS One


2020 Číslo 1